AVPAvePoint, Inc.

🇸🇬 Singapur Borsası
21.40
SGD
Analysis Scores
Lothien Robustness Score?
41/100
Moderate
Neden bu skor?
Damodaran ?
45/100
Dalio Risk ?
94/100
Piotroski ?
3/9
Weak
Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Graham ?
S$5.1
Pahalı
Active Metric?
4/4
Confidence?
75%
Lothien Robustness Summary
71/100
Lothien Sağlamlık: Güçlü (71/100)
Genel tablo olumlu. Finansal yapı sağlam, bazı riskler mevcut. | Kısa Vade: Olumlu | Uzun Vade: Nötr | Pozitif: 6 | Negatif: 3 | Nötr: 1
Net Kâr Pozitif
Son çeyrekte S$35M net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+80.8 arttı (S$20M → S$35M). Kısa vadede olumlu momentum.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+921.9 arttı. Büyüme trendi sağlıklı.
3 Çeyrek Üst Üste Artış
Son 3 çeyrek üst üste kâr artıyor. Güçlü yukarı trend devam ediyor.
Yüksek Net Kâr Marjı
Net kâr marjı %22.1. Her 100S$ satıştan 22S$ kâr kalıyor.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından S$513M fazla. Borç riski düşük.
Yüksek F/K Uyarısı
Trailing F/K: 49.5. Piyasa yüksek büyüme bekliyor ya da hisse pahalı. Büyüme gerçekleşmezse düşüş riski yüksek.
Yüksek PD/DD
PD/DD: 8.09. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Yüksek EV/EBITDA
EV/EBITDA: 60.2. Pahalı değerleme.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-16.3 düşebilir. Sonraki bilançoya dikkat.

Data date 2026-11-19 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-19
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Yüksek
252 days
Annual Volatility ?
%45.2
VaR 95% ?
%4.54
daily max loss
VaR 99% ?
%6.48
daily max loss
CVaR 95% ?
%5.86
expected loss (tail)
Max Drawdown ?
%37.6
19.12.2025 → 13.04.2026
Skewness ?
0.23
Parametrik%4.54
Historik%4.65
Cornish-Fisher%4.27
Return Distribution
Valuation
Potential?
-48.1%
ROIC ?
62.0%
DCF Value ?
10.72
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Son 6 çeyrek ardışık kâr
Fiyat TRAMA-99 üzerinde: %+9.7 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 19.50 SGD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %22.1
Net profit margin %22.1 — very strong. Compared to previous quarter +9.1 point increase.
ROE - Return on Equity (TTM) %13.4
ROE %13.4 — moderate return on equity.
EBITDA Margin %9.6
EBITDA margin %9.6 — moderate operational efficiency.
Gross Profit Margin %73.1
Gross profit per revenue %73.1. Strong pricing power.
Free Cash Flow Margin (TTM) %21.3
TTM Free Cash Flow is %21.3'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio 49.5x Sector: 15.2x
F/K 49.5x — sector median's (15.2x) %226 above. Expensive zone.
P/B Ratio 8.09x Sector: 2.02x
PD/DD 8.09x — sector median's %301 above. Expensive book value.
EV/EBITDA 60.2x Sector: 6.2x
EV/EBITDA 60.2x — sector median's (6.2x) %873 above. Expensive relative to EBITDA.
Indebtedness
Current Ratio 2.00x
Current ratio 2.00x — can comfortably cover short-term debts.
Net Debt / EBITDA 0.3x
Net Debt/EBITDA 0.3x — very low debt burden. Company can repay debt quickly.
Debt / Equity 0.04x
Low leverage — majority of assets financed by equity.
Growth
Revenue Growth (YoY) %+22.0
Revenue YoY %22.0 grew — healthy growth rate.
Net Profit Growth (YoY) %+921.9
Net profit YoY %921.9 increased (2026/6) — extraordinary profit growth.
Score Explanations
Lothien Robustness
41/100
Moderate robustness (41/100). Valuation and risk criteria give mixed signals. Detailed review recommended.
Moderate
Potential
-48.1%
Minus %48.1 expected value (11.11) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %75.
Components: PE target: 7.49 | P/B target: 5.63 | EV/EBITDA target: 5.35 | DCF target: 10.72
Damodaran Valuation
45/100
Low Damodaran score (45/100). DCF analysis does not support current price.
Weak
Dalio Risk Analysis
94/100
Low debt risk (94/100). Debt/EBITDA 0.3x — in healthy range.
Leverage: 96/100 | Debt Service: 100/100 | Quality: 75/100
ROIC - Return on Capital
%62.0
ROIC (%62.0) cost of capital 49.9 bps above → company creates value.
WACC: %12.1
DCF Discounted Cash Flow
10.72
DCF (10.72) current price %49.9 below — cash flows do not support current price.
Current price: 21.40
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
3/9
Weak Piotroski (3/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Weak
Graham Intrinsic Value
S$5.1
Expensive
⚖️ Sector Comparison
P/E Ratio
49.5x vs 15.2x
Sector median's %226 above — expensive
P/B Ratio
8.09x vs 2.02x
Compared to sector %301 more expensive (by book value)
EV/EBITDA
60.2x vs 6.2x
Compared to sector %873 higher EV/EBITDA
ROIC vs WACC
%62.0 vs %12.1 WACC
ROIC 49.9 bps above cost of capital
Net Profit Margin (TTM)
%15.3 vs %11.2 EBITDA margin
TTM net profit margin %15.3
TRAMA-99 Trend — Uptrend
Price (21.40), TRAMA-99 line's %9.7 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 21.40
TRAMA: 19.50
Difference: %+9.7
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
P/E Ratio ?
P/B Ratio ?
EBITDA ?
Net Working Capital ?
Current Ratio ?
AVP — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.